Neuland Laboratories

Neuland Laboratories Assets per Share

The Total Assets per Share of Neuland Laboratories (NEULANDLAB.NS) as of Nov 1, 2026 is 2,283.82 INR. In the previous year, Total Assets per Share was 1,699.05 INR — a change of 34.42% (higher).

Assets per Share

2,283.82INR

YoY

34.42%

Last updated:

Total Assets per Share of Neuland Laboratories is 2026 2,283.82 INR. Total Assets per Share of Neuland Laboratories was 2025 1,699.05 INR. It decreases by 34.42% higher compared to the previous year.

The Neuland Laboratories Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2019
881.02 INR
Jan 1, 2020
959.45 INR
Jan 1, 2021
1,032.57 INR
Jan 1, 2022
1,078.32 INR
Jan 1, 2023
1,231.31 INR
Jan 1, 2024
1,428.34 INR
Jan 1, 2025
1,699.05 INR
Jan 1, 2026
2,283.82 INR
The Neuland Laboratories Assets per Share history
YEARAssets per ShareYoY
2,283.82INR+34.42%
1,699.05INR+18.95%
1,428.34INR+16.00%
1,231.31INR+14.19%
1,078.32INR+4.43%
1,032.57INR+7.62%
959.45INR+8.90%
881.02INR+5.50%
835.07INR+20.98%
690.25INR+68.99%
408.46INR+2.45%
398.70INR+5.80%
376.84INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuland Laboratories stock

Total Assets per Share of Neuland Laboratories is 2,283.82 INR in 2026.

Total Assets per Share of Neuland Laboratories changed from 1,699.05 INR to 2,283.82 INR, representing a 34.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Neuland Laboratories

All Key Metrics — Neuland Laboratories